cytidylyl (3'-> 5') adenosine 5'-monophosphate | 15648-73-4

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - （3'->5'）-二核苷酸和类似物
• 英文名称: cytidylyl (3'-> 5') adenosine 5'-monophosphate
• 英文别名: [(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
• CAS: 15648-73-4
• 化学式: C₁₉H₂₆N₈O₁₄P₂
• 分子量: 652.408
• InChiKey: MMTJWPKMSKNVDK-KPKSGTNCSA-N

物化性质

• 沸点：
  1082.2±75.0 °C(Predicted)
• 密度：
  2.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -6.8
• 重原子数：
  43
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  330
• 氢给体数：
  8
• 氢受体数：
  18

反应信息

• 作为反应物：
  描述：

  cytidylyl (3'-> 5') adenosine 5'-monophosphate 在 palladium on activated charcoal 盐酸 、 N,N'-羰基二咪唑 作用下， 反应 130.33h， 生成 2'-O-(N-acetyl-L-phenylalanyl)-pCpA
  参考文献：
  名称：

  制备'2，（'3）-O-酰基-pCpA衍生物作为T4 RNA连接酶介导的“化学氨基酰化”的底物

  摘要：

  描述了'2（'3）-O-（氨基）酰基-pCpA衍生物的合成，并对其产物进行了化学表征，并在存在E的情况下作为T4 RNA连接酶的底物。大肠杆菌tRNA phe -C OH。如此衍生的修饰的（N-乙酰氨基）酰基-tRNA的特征在于其色谱和生化性质，以及它们在肽基转移酶反应中充当P-位tRNA供体的能力。

  DOI：

  10.1016/0040-4020(84)85106-6
• 作为产物：
  描述：

  2'-O-t-butyldimethylsilylcytidylyl (3'-> 5') adenosine 5'-monophosphate 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 反应 7.0h， 以83%的产率得到cytidylyl (3'-> 5') adenosine 5'-monophosphate
  参考文献：
  名称：

  制备'2，（'3）-O-酰基-pCpA衍生物作为T4 RNA连接酶介导的“化学氨基酰化”的底物

  摘要：

  描述了'2（'3）-O-（氨基）酰基-pCpA衍生物的合成，并对其产物进行了化学表征，并在存在E的情况下作为T4 RNA连接酶的底物。大肠杆菌tRNA phe -C OH。如此衍生的修饰的（N-乙酰氨基）酰基-tRNA的特征在于其色谱和生化性质，以及它们在肽基转移酶反应中充当P-位tRNA供体的能力。

  DOI：

  10.1016/0040-4020(84)85106-6

文献信息

• Facile Synthesis of <i>N</i>-Acyl-aminoacyl-pCpA for Preparation of Mischarged Fully Ribo tRNA
  作者：Marek Kwiatkowski、Jinfan Wang、Anthony C. Forster

  DOI：10.1021/bc500441b

  日期：2014.11.19

  Chemical synthesis of N-acyl-aminoacyl-pdCpA and its ligation to tRNA(minus) CA is widely used for the preparation of unnatural aminoacyl-tRNA substrates for ribosomal translation. However, the presence of the unnatural deoxyribose can decrease incorporation yield in translation and there is no straightforward method for chemical synthesis of the natural ribo version. Here, we show that pCpA is surprisingly stable to treatment with strong organic bases provided that anhydrous conditions are used. This allowed development of a facile method for chemical aminoacylation of pCpA. Preparative synthesis of pCpA was also simplified by using t-butyl-dithiomethyl protecting group methodology, and a more reliable pCpA postpurification treatment method was developed. Such aminoacyl-pCpA analogues ligated to tRNA(minus) CA transcripts are highly active in a purified translation system, demonstrating utility of our synthetic method.
• USE OF NUCLEIC ACID MOLECULES AS ANTIVIRAL AGENTS
  申请人：RIBOZYME PHARMACEUTICALS, INC.

  公开号：EP1098969A2

  公开（公告）日：2001-05-16
• CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US20200131669A1

  公开（公告）日：2020-04-30

  The present inventors have found that when screening for cyclic peptide compounds that can specifically bind to a target molecule, the use of a library including cyclic peptide compounds having a long side chain in the cyclic portion can improve the hit rate for cyclic peptide compounds that can specifically bind to the target molecule. Meanwhile, the present inventors have found that tryptophan and tyrosine residues, which have conventionally been used in oral low molecular-weight pharmaceuticals and are amino acid residues having an indole skeleton or a hydroxyphenyl group, are not suitable for peptides intended to attain high membrane permeability.
• US6500652B2
  申请人：——

  公开号：US6500652B2

  公开（公告）日：2002-12-31
• [EN] USE OF NUCLEIC ACID MOLECULES AS ANTIVIRAL AGENTS<br/>[FR] UTILISATION DE MOLECULES D'ACIDE NUCLEIQUE COMME AGENTS ANTIVIRAUX
  申请人：ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC.

  公开号：WO1999049031A1

  公开（公告）日：1999-09-30

  (EN) The invention provides antiviral compounds and compositions comprising a viral specific oligonucleotide. Also provided are methods to inhibit or treat viral infections with the compounds or compositions of the invention.(FR) La présente invention concerne des compositions et des composés antiviraux renfermant un oligonucléotide spécifique aux virus. Cette invention concerne par ailleurs des procédés qui empêchent ou traitent les infections virales avec les compositions ou les composés de cette invention.